Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Sonnet BioTherapeutics Holdings Inc is a biotechnology business based in the US. Sonnet BioTherapeutics shares (SONN) are listed on the NASDAQ and all prices are listed in US Dollars. Sonnet BioTherapeutics employs 9 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $0.32 |
|---|---|
| 52-week range | $0.29 - $3.42 |
| 50-day moving average | $0.49 |
| 200-day moving average | $1.00 |
| Wall St. target price | $3.17 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.02 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.3202 from 2022-01-25
| 1 week (2022-01-19) | -8.51% |
|---|---|
| 1 month (2021-12-23) | -28.84% |
| 3 months (2021-10-26) | -51.32% |
| 6 months (2021-07-26) | -68.91% |
| 1 year (2021-01-26) | -88.88% |
|---|---|
| 2 years (2020-01-24) | -52.90% |
| 3 years (2019-01-25) | 1.84 |
| 5 years (2017-01-26) | 0.3539 |
| Revenue TTM | $483,626 |
|---|---|
| Gross profit TTM | $-15,728,114 |
| Return on assets TTM | -84.78% |
| Return on equity TTM | -197.66% |
| Profit margin | 0% |
| Book value | $0.37 |
| Market capitalisation | $18.9 million |
TTM: trailing 12 months
We're not expecting Sonnet BioTherapeutics to pay a dividend over the next 12 months.
Sonnet BioTherapeutics's shares were split on a 1:26 basis on 1 April 2020. So if you had owned 26 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sonnet BioTherapeutics shares – just the quantity. However, indirectly, the new 2500% higher share price could have impacted the market appetite for Sonnet BioTherapeutics shares which in turn could have impacted Sonnet BioTherapeutics's share price.
Sonnet BioTherapeutics Holdings, Inc. , a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.